Tilray's Wild Ride: Cannabis Bill Boosts Stock Amidst Headwinds

Tilray stock jumped 5% on news of a House committee protecting state medical marijuana programs, but don't get too excited. Despite this boost, Tilray's facing major headwinds: a canceled DOJ cannabis rule, potential reverse stock split, and a massive $1 billion quarterly loss. Is this rally a blip in Tilray's volatile journey, or a sign of real change in the cannabis sector? Hosted on Acast. See acast.com/privacy for more information.